Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States

Leuk Lymphoma. 2013 Jul;54(7):1380-6. doi: 10.3109/10428194.2012.743655. Epub 2012 Nov 26.

Abstract

The epidemiology of splenic marginal zone lymphoma (SMZL) in the United States has not been addressed. Eight years of data (2001-2008) from 17 registries of the Surveillance, Epidemiology and End Results (SEER) program were used for this study. Of the 116,411 cases of non-Hodgkin lymphoma (NHL) in the registries, 763 (0.6%) were SMZL. The overall annual age-adjusted incidence was 0.13 per 100,000 persons per year. The annual percent change in age-adjusted incidence was 4.81% overall (p < 0.05), and significantly increasing trends were found for patients who were white, male or aged 70 years and older (p < 0.05). The relative 5-year overall survival rate for patients with SMZL was 81% (95% confidence interval 75-86%). The incidence of SMZL was highest among whites, males and older patients. A steadily increasing trend in incidence was observed for SMZL. The relative 5-year overall survival rate was high.

Publication types

  • Historical Article

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Female
  • History, 21st Century
  • Humans
  • Incidence
  • Lymphoma, B-Cell, Marginal Zone / epidemiology*
  • Lymphoma, B-Cell, Marginal Zone / history
  • Male
  • Middle Aged
  • Population Surveillance*
  • SEER Program
  • Splenic Neoplasms / epidemiology*
  • Splenic Neoplasms / history
  • Survival Analysis
  • United States / epidemiology
  • United States / ethnology